Free Trial

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 18 of 20

 
 

Arcellx (NASDAQ:ACLX)

Arcellx logoArcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). Read More 
 
Trailing Twelve Months EPS: ($1.03)
2024 EPS Estimate: ($1.65)
2025 EPS Estimate: ($2.05)

Current Stock Price
$75.41
Consensus Rating
Buy
Ratings Breakdown
15 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$78.00 (3.4% Upside)

 

The death of Nvidia? (Ad)

Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.

So go here now to read my new report The Big AI Die-Up… while you still can.